Scholars Central

Mini reviewPublished 30 Sep 2022

Chemoprevention in High Risk Women

Authors: Hongyu

Department of Medicine, Duke University Medical Center, Durham, U.S.A

Advances in Cancer Prevention

Volume 6 · Issue 5 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A number of second-line metastatic breast cancer trials have been conducted comparing the progestational agent, megesterol acetate, and a third-generation aromatase inhibitor following failure. At a minimum, these selective aromatase inhibitors demonstrated equivalent if not superior efficacy to megesterol acetate in patients with resistant advanced metastatic breast cancer as a second-line therapy, thus paving the way for direct head-to-head comparisons with th established first-line hormonal agent.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalAdvances in Cancer Prevention
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Hongyu”